The national debt is slated to rise by $23.9 trillion over the next decade, a sum that does not include trillions of dollars ...

Trump returns to the White House as the tenth wave of the COVID-19 pandemic once again inundates hospitals, while the last ...

Reforms of prescription drug pricing are finally taking full effect, just in time for Donald Trump and the Republicans to ...

Former Trump administration health official Joe Grogan applauds Biden proposal that Medicare and Medicaid cover GLP-1 ...

Antitrust regulators have reached a deal with Welsh, Carson, Anderson and Stowe that doesn’t penalize the private equity firm ...

Weight loss medications Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs.

Investors are appraising Trump policies' likely impact on stocks on the last trading day before the inauguration.

The Advocate highlights social inequality through original stories and opinions, and content generated by fellow NNPA and ...

Dan Tsai discusses how he ran Medicaid under Biden, and his fears for how Republicans might try to change the program.

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...